Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Trinity BiotechTRIB 38 3-1 Month Momentum % is -39.18% as of Aug. 05, 2026. GuruFocus rates TRIB with a GF Score™ of 38/100 and a GF Value™ of $22.86 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 854 Medical Devices & Instruments companies, Trinity Biotech ranks worse than 93.09% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-05), Trinity Biotech's 3-1 Month Momentum % is -39.18%.
The industry rank for Trinity Biotech's 3-1 Month Momentum % or its related term are showing as below:
TRIB's 3-1 Month Momentum % is ranked worse than 93.09% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: -5.795
vs TRIB: -39.18
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Trinity Biotech 3-1 Month Momentum % Related Terms
TRIB vs STME, VVOS, AIDX: 3-1 Month Momentum % Comparison
For the Medical Devices subindustry, Trinity Biotech's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Trinity Biotech 3-1 Month Momentum % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Trinity Biotech's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Trinity Biotech's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Trinity Biotech (TRIB) has a 3-1 Month Momentum % of -39.18% as of Aug. 05, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Trinity Biotech and its competitors. According to the industry distribution chart, Trinity Biotech ranks #795 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 93.1%.
Is Trinity Biotech's 3-1 Month Momentum % too high?
Trinity Biotech's current 3-1 Month Momentum % is -39.18%. Based on the distribution chart, Trinity Biotech ranks #795 out of 854 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Trinity Biotech has a GF Score™ of 38/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Trinity Biotech's 3-1 Month Momentum % compare to STME and VVOS?
According to the Medical Devices & Instruments industry distribution chart, Trinity Biotech ranks #795 out of 854 companies for 3-1 Month Momentum %. This places Trinity Biotech in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Devices & Instruments company?
A good 3-1 Month Momentum % depends on the Medical Devices & Instruments industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Trinity Biotech and its competitors. Trinity Biotech's current 3-1 Month Momentum % is -39.18%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Trinity Biotech stock overvalued right now?
Based on GuruFocus' analysis, Trinity Biotech (TRIB) is currently considered Possible Value Trap. The stock's GF Value™ is $22.86, compared to a current price of $11.00 — trading 51.9% below its estimated fair value. The current 3-1 Month Momentum % is -39.18%. Trinity Biotech's overall GF Score™ is 38/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Trinity Biotech (TRIB), the current 3-1 Month Momentum % is -39.18% as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Trinity Biotech (TRIB) Overvalued in 2026?
Based on GuruFocus' analysis, Trinity Biotech stock appears to be undervalued.
The current stock price of $11.00 is trading 51.9% below its estimated GF Value™ of $22.86.
GuruFocus considers Trinity Biotech to be Possible Value Trap.
Key valuation signals for TRIB:
3-1 Month Momentum %: -39.18%
GF Value™: $22.86 vs. price of $11.00 (51.9% below fair value)
No single metric tells the full story. See the TRIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has three segments, namely the Americas, Asia/Africa, and Europe, from which it derives a majority of its revenue from the Americas segment.
38GF Score
Get the complete analysis for TRIB
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TRIB has been successfully added to your 
